Info

Ronald Farkas, MD, PhD, clinical team leader, Division of Neurology Products Office of New Drugs fields questions during hearings over conflicting interpretations of findings from Sarepta's clinical trial of an experimental drug to treat Duchenne muscular dystrophy. Duchenne muscular dystrophy is a rare disease that strikes one in 3500 boys who typically don't survive into their 30's. Sarepta's drug is meant to treat a specific gene mutation. John Boal Photography

Add to Cart Add to Lightbox Download
Filename
JWB 042516 26Sarepta-059-final.JPG
Copyright
John Boal
Image Size
3000x2000 / 556.1KB
Contained in galleries
Ronald Farkas, MD, PhD, clinical team leader, Division of Neurology Products Office of New Drugs fields questions during hearings over conflicting interpretations of findings from Sarepta's clinical trial of an experimental drug to treat Duchenne muscular dystrophy. Duchenne muscular dystrophy is a rare disease that strikes one in 3500 boys who typically don't survive into their 30's. Sarepta's drug is meant to treat a specific gene mutation. John Boal Photography